Literature DB >> 27846572

A large fraction of HLA class I ligands are proteasome-generated spliced peptides.

Juliane Liepe1, Fabio Marino2,3, John Sidney4, Anita Jeko2,3, Daniel E Bunting5, Alessandro Sette4, Peter M Kloetzel6,7, Michael P H Stumpf5, Albert J R Heck2,3, Michele Mishto8,7.   

Abstract

The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules that elicit CD8+ T cell responses. Reports of proteasome-generated spliced epitopes exist, but they have been regarded as rare events. Here, however, we show that the proteasome-generated spliced peptide pool accounts for one-third of the entire HLA class I immunopeptidome in terms of diversity and one-fourth in terms of abundance. This pool also represents a unique set of antigens, possessing particular and distinguishing features. We validated this observation using a range of complementary experimental and bioinformatics approaches, as well as multiple cell types. The widespread appearance and abundance of proteasome-catalyzed peptide splicing events has implications for immunobiology and autoimmunity theories and may provide a previously untapped source of epitopes for use in vaccines and cancer immunotherapy.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27846572     DOI: 10.1126/science.aaf4384

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  134 in total

Review 1.  HIPs and HIP-reactive T cells.

Authors:  T A Wiles; T Delong
Journal:  Clin Exp Immunol       Date:  2019-06-17       Impact factor: 4.330

2.  Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.

Authors:  Shutao Mei; Rochelle Ayala; Sri H Ramarathinam; Patricia T Illing; Pouya Faridi; Jiangning Song; Anthony W Purcell; Nathan P Croft
Journal:  Mol Cell Proteomics       Date:  2020-05-01       Impact factor: 5.911

3.  The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes.

Authors:  Ernesto S Nakayasu; Wei-Jun Qian; Carmella Evans-Molina; Raghavendra G Mirmira; Decio L Eizirik; Thomas O Metz
Journal:  Expert Rev Proteomics       Date:  2019-06-24       Impact factor: 3.940

Review 4.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

5.  Comment on "A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands".

Authors:  Zach Rolfs; Markus Müller; Michael R Shortreed; Lloyd M Smith; Michal Bassani-Sternberg
Journal:  Sci Immunol       Date:  2019-08-16

6.  Proteolytic dynamics of human 20S thymoproteasome.

Authors:  Ulrike Kuckelkorn; Sabine Stübler; Kathrin Textoris-Taube; Christiane Kilian; Agathe Niewienda; Petra Henklein; Katharina Janek; Michael P H Stumpf; Michele Mishto; Juliane Liepe
Journal:  J Biol Chem       Date:  2019-03-26       Impact factor: 5.157

7.  Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics.

Authors:  Anthony W Purcell; Sri H Ramarathinam; Nicola Ternette
Journal:  Nat Protoc       Date:  2019-05-15       Impact factor: 13.491

8.  Spliced-peptide presentation.

Authors:  Laurie A Dempsey
Journal:  Nat Immunol       Date:  2016-11-16       Impact factor: 25.606

Review 9.  T1D Autoantibodies: room for improvement?

Authors:  Liping Yu; Zhiyuan Zhao; Andrea K Steck
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-08       Impact factor: 3.243

Review 10.  Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Authors:  Chung-Han Lee; Roman Yelensky; Karin Jooss; Timothy A Chan
Journal:  Trends Immunol       Date:  2018-05-08       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.